Cyclic Adenosine Monophosphate, Ventricular Fibrillation, and Antiarrhythmic Drugs

Overview

Journal Lancet

Publisher Elsevier

Specialty General Medicine

Date 1976 Feb 14

PMID 54744

Citations 14

Authors

T Podzuweit

W F Lubbe

L H Opie

Affiliations

Soon will be listed here.

Abstract

It is proposed that the development of ventricular fibrillation in the context of ischaemic heart-disease and myocardial infarction can be related to accumulation of cyclic adenosine 3',5' monophosphate (A.M.P.) in the ischaemic zone. The known electrophysiological and metabolic actions of cyclic A.M.P. are consonant with the hypothesis, which also provides a framework for the better understanding of the action of antiarrhythmic drugs.

Citing Articles

The drug risks of cilostazol: A pharmacovigilance study of FDA Adverse Event Reporting System database.

Peng L, Li X, Li J, Liu S, Liang G PLoS One. 2024; 19(12):e0314957.

PMID: 39630707 PMC: 11616863. DOI: 10.1371/journal.pone.0314957.

An endogenous protectant effect of cardiac cyclic GMP against reperfusion-induced ventricular fibrillation in the rat heart.

Pabla R, Moore P, Curtis M Br J Pharmacol. 1995; 116(7):2923-30.

PMID: 8680726 PMC: 1909229. DOI: 10.1111/j.1476-5381.1995.tb15946.x.

Phosphodiesterase III inhibitors: long-term risks and short-term benefits.

Cruickshank J Cardiovasc Drugs Ther. 1993; 7(4):655-60.

PMID: 8241008 DOI: 10.1007/BF00877818.

Long lasting anti-adrenergic effect of 7-oxo-prostacyclin in the heart: a cycloheximide sensitive increase of phosphodiesterase isoform I and IV activities.

Borchert G, Bartel S, Beyerdorfer I, Kuttner I, Szekeres L, Krause E Mol Cell Biochem. 1994; 132(1):57-67.

PMID: 8078509 DOI: 10.1007/BF00925675.

Evaluation of the effect of phosphodiesterase inhibitors on mortality in chronic heart failure patients. A meta-analysis.

Nony P, Boissel J, Lievre M, Leizorovicz A, Haugh M, Fareh S Eur J Clin Pharmacol. 1994; 46(3):191-6.

PMID: 8070498 DOI: 10.1007/BF00192547.